The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumocystis jiroveci pneumonia
Publications
A Case of Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection.
Case reports in nephrology and dialysis 2021 Jan-Apr;11;10-15 — 2021 Jan-Apr — 10-15
Pneumonia and Acute Kidney Injury Induced by Everolimus Treatment in a Patient with Metastatic Breast Cancer.
Case reports in oncology 2020 Jan-Apr;13;170-175 — 2020 Jan-Apr — 170-175
Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.
The European respiratory journal 2015 Sep;46;783-94 — 2015 Sep — 783-94
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer.
Medical mycology case reports 2014 Oct;6;34-6 — 2014 Oct — 34-6
Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.
Investigational new drugs 2014 Dec;32;1308-10 — 2014 Dec — 1308-10
A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
Japanese journal of clinical oncology 2013 May;43;559-62 — 2013 May — 559-62